<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941003-0-00073</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;314.95 <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Notice of certification of invalidity or  <!-- PJG 0012 frnewline --> noninfringement of a patent.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Notice of certification.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> For each patent that claims the listed drug or that claims a use for such listed drug for which the applicant is seeking approval and that the applicant certifies under &sect;314.94(a)(12) is invalid, unenforceable, or will not be infringed, the applicant shall send notice of such certification by registered or certified mail, return receipt requested to each of the following persons:  <!-- PJG 0012 frnewline --> (1) Each owner of the patent which is the subject of the certification or the representative designated by the owner to receive the notice. The name and address of the patent owner or its representative may be obtained from the United States Patent and Trademark Office; and  <!-- PJG 0012 frnewline --> (2) The holder of the approved application under section 505(b) of the act for the listed drug that is claimed by the patent and for which the applicant is seeking approval, or, if the application holder does not reside or maintain a place of business within the United States, the application holder's attorney, agent, or other authorized official. The name and address of the application holder or its attorney, agent, or authorized official may be obtained from the Division of Drug Information Resources (HFD&hyph;80), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.  <!-- PJG 0012 frnewline --> (3) This paragraph does not apply to a use patent that claims no uses for which the applicant is seeking approval.  <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sending the notice.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The applicant shall send the notice required by paragraph (a) of this section when it receives from FDA an acknowledgment letter stating that its abbreviated new drug application is sufficiently complete to permit a substantive review. At the same time, the applicant shall amend its abbreviated new drug application to include a statement certifying that the notice has been provided to each person identified under paragraph (a) of this section and that the notice met the content requirements under paragraph (c) of this section.  <!-- PJG 0012 frnewline --> (c)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Contents of a notice.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In the notice, the applicant shall cite section 505(j)(2)(B)(ii) of the act and shall include, but not be limited to, the following information:  <!-- PJG 0012 frnewline --> (1) A statement that FDA has received an abbreviated new drug application submitted by the applicant containing any required bioavailability or bioequivalence data or information.  <!-- PJG 0012 frnewline --> (2) The abbreviated application number.  <!-- PJG 0012 frnewline --> (3) The established name, if any, as defined in section 502(e)(3) of the act, of the proposed drug product.  <!-- PJG 0012 frnewline --> (4) The active ingredient, strength, and dosage form of the proposed drug product.  <!-- PJG 0012 frnewline --> (5) The patent number and expiration date, as submitted to the agency or as known to the applicant, of each patent alleged to be invalid, unenforceable, or not infringed.  <!-- PJG 0012 frnewline --> (6) A detailed statement of the factual and legal basis of the applicant's opinion that the patent is not valid, unenforceable, or will not be infringed. The applicant shall include in the detailed statement:  <!-- PJG 0012 frnewline --> (i) For each claim of a patent alleged not to be infringed, a full and detailed explanation of why the claim is not infringed.  <!-- PJG 0012 frnewline --> (ii) For each claim of a patent alleged to be invalid or unenforceable, a full and detailed explanation of the grounds supporting the allegation.  <!-- PJG 0012 frnewline --> (7) If the applicant does not reside or have a place of business in the United States, the name and address of an agent in the United States authorized to accept service of process for the applicant.  <!-- PJG 0012 frnewline --> (d)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Amendment to an abbreviated application.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> If an abbreviated application is amended to include the certification described in &sect;314.94(a)(12)(i)(A)( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 4 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), the applicant shall send the notice required by paragraph (a) of this section at the same time that the amendment to the abbreviated application is submitted to FDA.  <!-- PJG 0012 frnewline --> (e)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Documentation of receipt of notice.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The applicant shall amend its abbreviated application to document receipt of the notice required under paragraph (a) of this section by each person provided the notice. The applicant shall include a copy of the return receipt or other similar evidence of the date the notification was received. FDA will accept as adequate documentation of the date of receipt a return receipt or a letter acknowledging receipt by the person provided the notice. An applicant may rely on another form of documentation only if FDA has agreed to such documentation in advance. A copy of the notice itself need not be submitted to the agency.  <!-- PJG 0012 frnewline --> (f)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Approval.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> If the requirements of this section are met, FDA will presume the notice to be complete and sufficient, and it will count the day following the date of receipt of the notice by the patent owner or its representative and by the approved application holder as the first day of the 45-day period provided for in section 505(j)(4)(B)(iii) of the act. FDA may, if the applicant provides a written statement to FDA that a later date should be used, count from such later date.  <!-- PJG 0012 frnewline --> 8. Section 314.101 is amended by revising paragraph (e) to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;314.101 <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Filing an application and an abbreviated antibiotic application and receiving an abbreviated new drug application.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (e) The agency will refuse to file an application or abbreviated antibiotic application or will consider an abbreviated new drug application not to have been received if any of the following applies:  <!-- PJG 0012 frnewline --> (1) The drug product is subject to licensing by FDA under the Public Health Service Act (42 U.S.C. 201  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> et seq. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) and subchapter F of this chapter.  <!-- PJG 0012 frnewline --> (2) In the case of a 505(b)(2) application or an abbreviated new drug application, the drug product contains the same active moiety as a drug that:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            